Menu
Sponsor: Phost’In Therapeutics SAS
Design: Phase I (First-in-Human), multicenter, international study
Indication: Adult patients with advanced or metastatic solid malignancies with radiologically documented progression on a previous line of treatment and for which effective treatment options do not exist
EU Countries: Italy, France
Sponsor: Fondazione Michelangelo Onlus
Design: Phase III, randomized, multicenter, international study
Indication: women with a diagnosis of early high-risk invasive unilateral, HER2-positive breast cancer suitable for neoadjuvant therapy
Conduct: this multicenter trial is conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo, and conducted in collaboration with regional European and non-European research groups and other sites.
EU Countries: Italy, Germany, Austria, Belgium, Spain, Romania
Non-EU Countries: Taiwan
Sponsor: Fondazione Michelangelo Onlus
Design: Phase III, randomized, multicenter, international study
Indication: Women with a diagnosis of invasive unilateral early high-risk and locally advanced or inflammatory, triple negative (HER2-negative and ERnegative and PgR-negative) breast cancer of high proliferation or grade suitable for neoadjuvant therapy
Conduct: this multicenter trial is conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo, and conducted in collaboration with regional European and non-European participating research groups and other sites.
EU Countries: Italy, Germany, Austria, Spain, Ireland
Non-EU Countries: Russia, Taiwan
Sponsor: Fondazione Michelangelo Onlus
Design: Phase III, randomized, multicenter, international study
Indication: Patients with HER2-negative, non metastatic unilateral breast cancer who are at risk of disease recurrence and suitable for neoadjuvant chemotherapy
Conduct: this multicenter trial is conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo, and conducted in collaboration with regional European and non-European research groups and other sites.
EU Countries: Italy, Germany, Austria, Spain
Non-EU Countries: Russia, Singapore, Australia
Sponsor: Fondazione Michelangelo Onlus
Design: Exploratory Phase II with parallel cohorts
Indication: Women with a diagnosis of invasive unilateral non metastatic ERpositive
breast cancer expressing HER2 and suitable for neoadjuvant therapy
Conduct: this multicenter trial was conducted under the sponsorship and overall trial oversight of the Fondazione Michelangelo in Italy
